This has been previously demonstrated in vivo with a DC-based vaccine containing a miR148a inhibitor, poly I:C (TLR3 agonist), and tumor antigen, which promoted enhanced anti-tumor immunity and survival by expanding mature DCs and suppressing Treg and MDSC development (150). Here, TLR3 is linked to neoplasm.